Skip to main content
. 2019 Aug 31;29(Suppl 1):1–9. doi: 10.1007/s10286-019-00630-y

Fig. 2.

Fig. 2

Autonomic symptoms at enrollment or first visit in patients with hereditary ATTR amyloidosis enrolled in the Neuro-TTR trial and the THAOS registry. Entry criteria for Neuro-TTR trial was disease stage I-II (patients still able to walk). The THAOS registry had no entry limitations and patients could be enrolled at any stage, including asymptomatic patients